» Articles » PMID: 35222550

Fast and Easy Nanopore Sequencing Workflow for Rapid Genetic Testing of Familial Hypercholesterolemia

Overview
Journal Front Genet
Date 2022 Feb 28
PMID 35222550
Authors
Affiliations
Soon will be listed here.
Abstract

Familial hypercholesterolemia (FH) is an autosomal dominant lipid metabolism disorder characterized by severely elevated plasma low-density lipoprotein cholesterol levels. The disease is caused by mutations in 3 genes (, and ) while over 90% of the mutations are located within the gene. Thus, genetic analysis of the gene is the first step in the genetic diagnosis of FH. However, conventional methods like Sanger and NextGen sequencing are still costly and time-consuming. In contrast, Oxford Nanopore technology sequencing is an emerging third-generation sequencing technology featured by easy operability, low cost, small size and the capability of parallel sample sequencing. Here, we present an easy Nanopore-sequencing-based workflow for the rapid genetic testing of FH taking only 3 days and costing less than $50 per sample without the requirement for deep bioinformatic knowledge. Using our workflow, we were able to identify the underlying pathogenic variants of 10 FH patients including one novel, not yet recorded pathogenic variants. Our workflow allows the rapid evaluation of the pathogenic variants by utilizing detailed variant information from Ensembl. Additionally, our workflow is not restricted to sequencing the gene alone but can be easily adapted to the other FH-causing genes and more importantly, to any desired gene contributing to any hereditary disease. Therefore, our workflow is an attractive opportunity for every diagnostic laboratory to offer fast and easy in-house genetic diagnostics.

Citing Articles

Genewise detection of variants in gene using nanopore sequencing.

Ghukasyan L, Khachatryan G, Sirunyan T, Minasyan A, Hakobyan S, Chavushyan A Front Genet. 2024; 15:1493295.

PMID: 39678383 PMC: 11638185. DOI: 10.3389/fgene.2024.1493295.


Calling and Phasing of Single-Nucleotide and Structural Variants of the Gene Using Oxford Nanopore MinION.

Nazarenko M, Sleptcov A, Zarubin A, Salakhov R, Shevchenko A, Tmoyan N Int J Mol Sci. 2023; 24(5).

PMID: 36901902 PMC: 10003201. DOI: 10.3390/ijms24054471.


Application of Long-Read Nanopore Sequencing to the Search for Mutations in Hypertrophic Cardiomyopathy.

Salakhov R, Golubenko M, Valiakhmetov N, Pavlyukova E, Zarubin A, Babushkina N Int J Mol Sci. 2022; 23(24).

PMID: 36555486 PMC: 9779642. DOI: 10.3390/ijms232415845.

References
1.
Steinhaus R, Proft S, Schuelke M, Cooper D, Schwarz J, Seelow D . MutationTaster2021. Nucleic Acids Res. 2021; 49(W1):W446-W451. PMC: 8262698. DOI: 10.1093/nar/gkab266. View

2.
Nordestgaard B, Chapman M, Humphries S, Ginsberg H, Masana L, Descamps O . Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J. 2013; 34(45):3478-90a. PMC: 3844152. DOI: 10.1093/eurheartj/eht273. View

3.
Rang F, Kloosterman W, de Ridder J . From squiggle to basepair: computational approaches for improving nanopore sequencing read accuracy. Genome Biol. 2018; 19(1):90. PMC: 6045860. DOI: 10.1186/s13059-018-1462-9. View

4.
Howe K, Achuthan P, Allen J, Allen J, Alvarez-Jarreta J, Amode M . Ensembl 2021. Nucleic Acids Res. 2020; 49(D1):D884-D891. PMC: 7778975. DOI: 10.1093/nar/gkaa942. View

5.
Aatre R, Day S . Psychological issues in genetic testing for inherited cardiovascular diseases. Circ Cardiovasc Genet. 2011; 4(1):81-90. DOI: 10.1161/CIRCGENETICS.110.957365. View